If you don’t have access to these meds through your employer, this may be an option worth bringing up. 

The $449 cost (plus whatever fees come from the program administrator - some of which have lower overheads than others - is likely lower than the net prices plans/employers are receiving via insurance after rebates from the manufacturer (especially because the PBMs have not been passing through 100% of the rebates).

Employers would then determine how much they would shoulder and how much to pass on to their employees.

“Through this employer platform, Lilly's Zepbound® (tirzepatide) KwikPen® is available from Lilly to network pharmacies at a discounted price of $449 for all doses. Final cost to the employer may vary based on their choice of pharmacy and program administrator; and out-of-pocket patient costs for employees will vary based on the costshare model an employer chooses and the dispensing and service fees agreed to with independent program administrators. Fundamentally, this approach provides employees access to obesity management medicines at lower out-of-pocket cost.”

“Lilly will continue to grow the program administrator options for employers on the platform, which already includes 9amHealth, Andel, Calibrate Health, Crux Health, eMed, FlyteHealth, Form Health, Goodpath, GoodRx, Ilant Health, Mark Cuban Cost Plus Drug Company, Onsera Health, ReviveHealth, SALTA Direct Primary Care, Sesame, Teladoc Health, Transcarent and Waltz Health. Employers, benefit consultants, or other stakeholders interested in learning more about the program should contact EmployerAccess@lilly.com.”

Talk to your decision makers: Lilly launches new Direct to Employer Option for Zepbound KwikPen at $449 all doses with over fifteen program administrators